Product Description
Strong evidence now demonstrates that artemether-lumefantrine (AL) (Coartem) is effective and safe in the treatment of malaria in pregnancy.
Mechanisms of Action: Protein Synthesis Inhibitor,DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Malaria
Phase 3: Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2012-001333-14 | P3 |
Completed |
Malaria, Falciparum |
2013-01-27 |
2025-06-26 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
|
| Coartem® | P4 |
Completed |
Malaria |
2012-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|